Program
Empagliflozin/Linagliptin
Its studies are mostly in Diabetes Mellitus, Type 2, led by Humanis Saglık Anonim Sirketi.
Furthest: phase 1, since Apr 10, 20252 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Humanis Saglık Anonim Sirketi | 20 open or running | phase 1since Apr 10, 2025 | Apr 10, 2025 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 10, 2025First study: phase 1 study in Diabetes Mellitus, Type 2First studyNCT06932159 · 40 enrolled · India
- Jun 18, 2025Phase 1 study in Diabetes Mellitus, Type 2NCT07039890 · 40 enrolled · India
TargetBeta
“A fixed dose combination of empagliflozin, an inhibitor of sodium-glucose co-transporter 2 (SGLT2; SLC5A2), and linagliptin, a dihydropurinedione-based inhibitor of dipeptidyl peptidase 4 (DPP-4), with antihyperglycemic activity”NCIt, by rule
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07039890Diabetes Mellitus, Type 2 · India | 1 | Completed | May 14, 2025 | 40 |
| NCT06932159Diabetes Mellitus, Type 2 · India | 1 | Completed | Mar 7, 2025 | 40 |
How it is read
Names in the registry
- “Glyxambi film-coated tablets”, 2 entries
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.